Company
United StatesPublic company, NASDAQ: AMGNAmgen Inc. (NASDAQ: AMGN), Louisville, KY – FDA Inspections
Inspection records and compliance data for Amgen Inc. in Louisville, Kentucky. 2 FDA inspections on record, last inspected November 06, 2025. Publicly traded as NASDAQ: AMGN.
Company Profile
This profile covers Amgen Inc. based in Louisville, Kentucky, United States.
FDA Inspection History
- FDA inspections
- 2
- OAI
- 0
- VAI
- 0
- NAI
- 2
- Form 483s
- 0
- Warning letters
- 0
First inspected July 30, 2024. Last inspected November 6, 2025.
FDA inspections (2)
| Date | Result | FDA center(s) | Insp. # |
|---|---|---|---|
| November 6, 2025 | NAI | Biologics · Human Cellular, Tissue, and Gene Therapies | 1293010 |
| July 30, 2024 | NAI | Human Drugs · Drug Quality Assurance | 1234412 |
FDA documents
No Form 483s, Warning Letters or EIRs on record.
Related Companies (10)
Companies with similar regulatory profiles, compliance history, and operations.
Company Information
Name
Amgen Inc.
Stock ticker
AMGN
Exchange
NASDAQ
Share price
$467.06
Market cap
$252.6B
Price as of
November 13, 2026
FEI Number
3003750095
Address
12000 Plantside Dr, Louisville, Kentucky 40299, United States
Country
United States
ID: ebaa268e-d67a-4623-8e1b-ed5f19dbbf2b